Well said Stezza and your view point closely resembles my...

Well said Stezza and your view point closely resembles my own....

The facts as we know them, The DurAVR is clearly best in class and is being advocated by many of the best TAVR doctors in the world.

We also know that several global major healthcare companies, Edwards and Johnson&Johnson amongst others, are currently very active in the interventional cardiac space.

Add to this that the two current major TAVR companies, Edwards and Medtronic, BOTH brought TAVR's to market not on products that they designed and built, rather on TAVR devices they bought, so the precedence is there for NEW entrants to the TAVR field.

There will undoubtedly be more capital raisings yet the IP value here, the value of the DurAVR currently, far exceeds the current market cap, so with patience current investors should be greatly rewarded in the future.